Press Release—Awareness and Patient Recruitment for IPF Clinical Trial

Responsum Health To Aid In Patient Recruitment for Idiopathic Pulmonary Fibrosis Clinical Trial
New initiative to raise clinical trial awareness and pre-screen IPF patients

​[WASHINGTON, D.C., Dec. 14, 2020]Today, Responsum Health (Responsum), an innovative developer of personalized patient apps and chronic disease knowledge communities, begins a new initiative to raise awareness, support patient recruitment, and pre-screen idiopathic pulmonary fibrosis (IPF) patients for the ISABELA1 clinical study.

IPF is a chronic lung disease where the lung tissue becomes thick and stiff, forming scar tissue in the lungs. The scarring (fibrosis) worsens over time, which makes it difficult for those with IPF to breathe deeply and prevents the lungs from taking in a sufficient amount of oxygen. 

While there is currently no cure for the disease, ziritaxestat (GLPG1690) is the investigational add-on medication (taken in addition to one’s standard treatment as prescribed by one’s doctor) being studied in this clinical trial. The goal of this medication is to work in conjunction with patients’ current treatments for lung function and IPF in general. This experimental medication is not approved by the FDA or any regulatory authorities for any use outside of clinical trials.

Responsum Health will provide patients with information about clinical trials, their benefits, and their risks, in addition to details about the ISABELA1 clinical research study and who qualifies. On the Responsum Health website, there is a pre-screening form to be completed by IPF patients interested in participating. Upon completion, a phone interview will be scheduled for patients who meet the study’s qualifications.

“We believe in educating and empowering patients to become informed stakeholders in their own healthcare, and this initiative to facilitate patient access to clinical trials fulfills our mission in so many ways,” said Responsum Health Founder and CEO Andrew Rosenberg. “We couldn’t be more excited to share with the pulmonary fibrosis community this opportunity to better understand their disease and contribute information that may be helpful in developing new therapies in the future.” 

About Responsum Health

Responsum Health’s mission is to build and support online knowledge communities for chronic disease patients. The company offers a free, revolutionary patient engagement platform that monitors, searches, and curates the internet to generate a personalized Newsfeed of article summaries, which are vetted by Responsum’s patient group partners. Each comprehensive platform enables patients to comment on and rate articles, as well as share them with their professional care team and loved ones. Responsum also helps patients to better organize their health information, find local patient support groups and services, and support one another through a moderated, disease-specific social wall.


For more information, please contact Bridget Greinke at or (202) 480-9607. You can also visit our website at